Por: The Hill Health December 15, 2022
Pfizer has inked a deal with a Chinese-based pharmaceutical company to sell the COVID-19 antiviral Paxlovid in the country, . The announcement with China Meheco Group, which Bloomberg reported was made in a filing with the Shanghai stock exchange, comes as China faces a surge in coronavirus infections as it eases its “zero COVID” policy. Official case counts on the mainland have declined in recent days, but the decline comes as the country... + full article
Time USA Health November 30, 2022
Months after catching COVID-19 in December 2021, Lavanya Visvabharathy was still and suffering from symptoms including headaches and intense fatigue. So Visvabharathy, a research assistant professor of neurology at the Northwestern University Feinberg School of Medicine who has... + más
Covid-19 treatment Paxlovid can interact with common heart medications, doctors warn | CNN
For some COVID patients, 'Paxlovid rebound' has nothing to do with Paxlovid | Los Angeles Times
Los Angeles Times USA Science November 14, 2022
This is a story about a COVID-19 medication, a nasty trick the coronavirus sometimes plays on its victims, and how the two became a pandemic couple called “Paxlovid rebound.” It's also a story about how looks can be deceiving. Americans have been quick to embrace the... + más
Paxlovid rebound more common than initially thought, doctors say | ABC News
ABC News USA Health November 10, 2022
Six months ago, Dr. Joseph Boselli said he was prescribing the antiviral drug Paxlovid to nearly everyone who turned up at his practice with COVID.Now, the internal medicine physician at Jefferson Health in Philadelphia said he's reserving it mostly for people who are... + más
CNN USA Health November 07, 2022
CNN — Paxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according to a by researchers at the US Department of Veterans Affairs. The study, posted online as a preprint on Saturday, analyzed... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
MarketWatch USA Business November 01, 2022
Pfizer’s CFO David Denton cited strong performance from the company’s Paxlovid and Eliquis products, particularly in the U.S., as well as the “continued impressive launch” of the Prevnar 20 vaccine for adults in the U.S. Paxlovid is an antiviral used to treat COVID-19,... + más
Pfizer climbs on strong Q3 results, raised outlook | MarketWatch
Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC
CNN USA Health October 14, 2022
CNN — Covid-19 patients with a history of cardiovascular disease are at an increased risk of developing severe illness and could benefit most from the Covid-19 treatment Paxlovid – but there’s a catch. Paxlovid can have dangerous interactions with some of the most... + más
Pfizer pledges $120M to produce oral COVID-19 treatment Paxlovid at Michigan factory | New York Daily News
Study finds Paxlovid can interact badly with some heart medications, and White House renews COVID emergency through Jan. 11 | MarketWatch
About iurex | Privacy Policy | Disclaimer |